KVUE logo

Kenvue Inc. Stock Price

NYSE:KVUE Community·US$34.8b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 108 Fair Values set on narratives written by author

KVUE Share Price Performance

US$18.14
-3.51 (-16.21%)
US$19.50
Fair Value
US$18.14
-3.51 (-16.21%)
7.0% undervalued intrinsic discount
US$19.50
Fair Value
Price US$18.14
AnalystConsensusTarget US$19.50
julio US$25.09

KVUE Community Narratives

·
Fair Value US$19.5 7.0% undervalued intrinsic discount

Analyst Commentary Highlights Legal Risks and Valuation Adjustments for Kenvue Amid Market Uncertainty

0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
Fair Value
·
Fair Value US$25.09 27.7% undervalued intrinsic discount

J&J spinoff

1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
US$25.09
27.7% undervalued intrinsic discount
Fair Value
Revenue
8.7% p.a.
Profit Margin
13.3%
Future PE
24x
Price in 2034
US$59.35

Trending Discussion

Updated Narratives

KVUE logo

J&J spinoff

Fair Value: US$25.09 27.7% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KVUE logo

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Fair Value: US$19.5 7.0% undervalued intrinsic discount
52 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record and fair value.

2 Risks
3 Rewards

Kenvue Inc. Key Details

US$15.3b

Revenue

US$6.3b

Cost of Revenue

US$9.0b

Gross Profit

US$7.3b

Other Expenses

US$1.6b

Earnings

Last Reported Earnings
Mar 29, 2026
Next Reporting Earnings
n/a
0.84
58.60%
10.61%
81.6%
View Full Analysis

About KVUE

Founded
2022
Employees
21890
CEO
Kirk Perry
WebsiteView website
www.kenvue.com

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Recent KVUE News & Updates

Seeking Alpha Jun 09

Kenvue: After A Disappointing 3 Years, Kimberly-Clark's Gamble Could Revive Growth

Summary Kenvue Inc. faces near-term headwinds but offers long-term income potential, especially with its pending merger with Kimberly-Clark. Recent earnings showed resilience: Q1 revenue grew 4.5% to $3.91B and EPS rose to $0.32, despite macroeconomic pressures. The KVUE-KMB merger promises $2.1B in run-rate synergies, but meaningful growth is unlikely for 3–5 years amid inflation and regulatory scrutiny. With a forward P/E under 15x and a ~5% yield, KVUE stock is a solid hold; risks center on merger approval and ongoing margin pressures. Read the full article on Seeking Alpha
Narrative Update Jun 08

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Analysts slightly lifted their fair value estimate for Kenvue to $19.50, a modest move supported by small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, even as recent Street research from Citi, Barclays and UBS reflects more cautious price targets. Analyst Commentary Recent price target trims of around $1 from several firms signal that the Street is fine tuning expectations rather than making a wholesale shift in its view on Kenvue.

Recent updates

No updates